Paper42352257
Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis.
Ma BF and 9 others. Biomolecules, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis. Papers, record 42352257. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42352257
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| STAT3 Transcription Factor | Major topic |
| Interleukin-6 | Major topic |
| Esophageal Squamous Cell Carcinoma | Major topic |
| Transcription Factor AP-1 | Major topic |
| Esophageal Neoplasms | Major topic |
| Piperidines | Major topic |
| Humans | |
| Animals | |
| Signal Transduction | |
| Mice | |
| Cell Line, Tumor | |
| Quinolizidines | |
| Apoptosis | |
| Cell Proliferation | |
| Quinolizidine Alkaloids | |
| Male | |
| Cisplatin |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82460714 | National Natural Science Foundation of China | PubMed |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35453655 | Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases. | Biomedicines | 2022 | https://conductscience.org/library/papers/35453655 | PubMed |
| 2 | 29056830 | Aloperine Protects Mice against DSS-Induced Colitis by PP2A-Mediated PI3K/Akt/mTOR Signaling Suppression. | Mediators Inflamm | 2017 | https://conductscience.org/library/papers/29056830 | PubMed |
| 3 | 41369383 | The Interplay Between Esophageal Adenocarcinoma and Its Tumor Microenvironment: Toward Innovative Therapies. | Cells | 2025 | https://conductscience.org/library/papers/41369383 | PubMed |
| 4 | 39166458 | Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome-lysosome Fusion in NSCLC. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39166458 | PubMed |
| 5 | 32416073 | Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416073 | PubMed |
| 6 | 33239133 | Aloperine can reverse the cisplatin resistance of colorectal cancer cells via suppressing the HIF-1α/ERK signaling pathway. | Pharmazie | 2020 | https://conductscience.org/library/papers/33239133 | PubMed |
| 7 | 40427135 | CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40427135 | PubMed |
| 8 | 38924996 | KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression. | Drug Resist Updat | 2024 | https://conductscience.org/library/papers/38924996 | PubMed |
| 9 | 32144444 | Aloperine suppresses LPS-induced macrophage activation through inhibiting the TLR4/NF-κB pathway. | Inflamm Res | 2020 | https://conductscience.org/library/papers/32144444 | PubMed |
| 10 | 40169778 | An organoid library of human esophageal squamous cell carcinomas (ESCCs) uncovers the chemotherapy-resistant ESCC features. | Commun Biol | 2025 | https://conductscience.org/library/papers/40169778 | PubMed |
| 11 | 29785122 | Aloperine executes antitumor effects through the induction of apoptosis and cell cycle arrest in prostate cancer in vitro and in vivo. | Onco Targets Ther | 2018 | https://conductscience.org/library/papers/29785122 | PubMed |
| 12 | 39661488 | Hypoxia-Induced Senescent Fibroblasts Secrete IGF1 to Promote Cancer Stemness in Esophageal Squamous Cell Carcinoma. | Cancer Res | 2025 | https://conductscience.org/library/papers/39661488 | PubMed |
| 13 | 40558556 | A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A. | Cells | 2025 | https://conductscience.org/library/papers/40558556 | PubMed |
| 14 | 37827946 | Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis. | Clin Oncol (R Coll Radiol) | 2024 | https://conductscience.org/library/papers/37827946 | PubMed |
| 15 | 35721119 | Aloperine Ameliorates IMQ-Induced Psoriasis by Attenuating Th17 Differentiation and Facilitating Their Conversion to Treg. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35721119 | PubMed |
| 16 | 39419971 | The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma. | Nat Commun | 2024 | https://conductscience.org/library/papers/39419971 | PubMed |
| 17 | 35671803 | The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. | Gastroenterology | 2022 | https://conductscience.org/library/papers/35671803 | PubMed |
| 18 | 34883316 | Aloperine inhibits colorectal cancer cell proliferation and metastasis progress via regulating miR-296-5p/STAT3 axis. | Tissue Cell | 2022 | https://conductscience.org/library/papers/34883316 | PubMed |
| 19 | 38286054 | Serine/Threonine Kinase (STK) 33 promotes the proliferation and metastasis of human esophageal squamous cell carcinoma via inflammation-related pathway. | Pathol Res Pract | 2024 | https://conductscience.org/library/papers/38286054 | PubMed |
| 20 | 33390169 | Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33390169 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| FOS | 2353 | PubTator's text mining | https://conductscience.org/library/genes/2353 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| JUN | 3725 | PubTator's text mining | https://conductscience.org/library/genes/3725 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| STAT3 | 6774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42352257
GET https://conductscience.org/api/papers/v1/42352257/references?page=2